• News
  • SAN DIEGO
  • BioTech

Sorrento Therapeutics appoints Mark Durand to board

Sorrento Therapeutics Inc. (Nasdaq: SRNE) a San Diego late-stage clinical oncology company developing new treatments for cancer and associated pain, has added Mark W. Durand to its board of directors.

Durand has nearly 28 years of broad pharmaceutical industry experience in a variety of leadership roles for both branded and generic drugs. Durand is currently an independent strategic consultant for pharmaceutical firms.

“Mark is a dedicated, high energy executive with vast experience in the pharmaceutical industry,” said Henry Ji, president and CEO of Sorrento Therapeutics. “He has made significant contributions in the development and commercialization of multiple therapeutic drugs.”

Durand has been the chief financial officer and senior vice president of finance and business development for Watson Pharmaceuticals (now Actavis) and at Teva Americas.

He began his career at Bristol-Myers Squibb in 1986 and held the position of vice president of finance and business development.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Sorrento Therapeutics Inc.

Company Website

6042 Cornerstone Ct. West Ste., B
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
SRNE
8.98
  0.38  
+ 4.42%
427,415,000
26.8
3.41

Sorrento Therapeutics Inc. Executive(s):

Henry Ji

  • Chief Executive Officer

Richard Vincent

  • Chief Financial Officer

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Subscribe Today!